Alessandro Sette Selected Research

Peptides (Polypeptides)

6/2022	T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Have a Predominant CD4+ T Helper Response to SARS-CoV-2 Peptides and Numerous Virus-Specific CD4- CD8- Double-Negative T Cells.
1/2022	Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens.
1/2022	Correction: Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.
1/2022	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1.
4/2021	Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine.
1/2021	Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals.
1/2021	Evaluation of ELISA-Based Multiplex Peptides for the Detection of Human Serum Antibodies Induced by Zika Virus Infection across Various Countries.
1/2021	IgG Epitopes Processed and Presented by IgG+ B Cells Induce Suppression by Human Thymic-Derived Regulatory T Cells.
1/2021	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
1/2021	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Sette Research Topics

Disease

122	Infections 08/2022 - 09/2002
51	COVID-19 08/2022 - 01/2020
39	Neoplasms (Cancer) 02/2022 - 01/2002
29	Hypersensitivity (Allergy) 01/2021 - 03/2007
25	Tuberculosis (Tuberculoses) 12/2021 - 09/2007
18	Communicable Diseases (Infectious Diseases) 01/2022 - 01/2002
18	Virus Diseases (Viral Diseases) 01/2022 - 09/2002
13	Asthma (Bronchial Asthma) 10/2021 - 08/2012
12	Human Influenza (Influenza) 03/2022 - 01/2007
12	Dengue (Dengue Fever) 01/2020 - 01/2013
9	HIV Infections (HIV Infection) 01/2020 - 04/2005
8	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 10/2009
8	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2017
8	Whooping Cough (Pertussis) 11/2021 - 05/2014
8	Persistent Infection 01/2021 - 10/2003
8	Malaria 01/2019 - 07/2006
8	Smallpox (Variola) 12/2013 - 01/2005
7	Multiple Sclerosis 08/2022 - 01/2004
7	Viremia 11/2021 - 06/2005
7	Melanoma (Melanoma, Malignant) 12/2015 - 05/2002
6	Atherosclerosis 07/2022 - 01/2013
6	Inflammation (Inflammations) 03/2022 - 05/2007
6	Rheumatoid Arthritis 01/2021 - 07/2003
6	Acquired Immunodeficiency Syndrome (AIDS) 11/2020 - 11/2002
6	Celiac Disease (Celiac Sprue) 01/2017 - 03/2003
6	Vaccinia 12/2013 - 09/2005
5	Zika Virus Infection 01/2022 - 12/2017
5	Toxoplasmosis 01/2017 - 05/2010
4	Disease Progression 11/2021 - 06/2008
4	Yellow Fever 11/2020 - 06/2010
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 06/2012
3	Coinfection 01/2022 - 04/2006
3	Fever (Fevers) 01/2022 - 12/2009
3	Latent Tuberculosis 10/2021 - 09/2007
3	Granuloma 01/2021 - 12/2018
3	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2019
3	Severe Dengue 01/2019 - 08/2015
3	Tetanus 01/2018 - 01/2017
3	Alopecia Areata 01/2018 - 11/2015
3	Infectious Ectromelia 09/2014 - 01/2005
3	Arenaviridae Infections 06/2010 - 02/2007
2	Pain (Aches) 08/2022 - 04/2021

Drug/Important Bio-Agent (IBA)

132	EpitopesIBA 07/2022 - 01/2002
114	VaccinesIBA 08/2022 - 01/2002
80	Peptides (Polypeptides)IBA 06/2022 - 05/2002
74	AntigensIBA 03/2022 - 05/2002
51	Proteins (Proteins, Gene)FDA Link 06/2022 - 09/2002
45	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2022 - 09/2003
23	CytokinesIBA 07/2022 - 11/2004
20	AllergensIBA 10/2021 - 09/2009
14	AntibodiesIBA 01/2022 - 12/2009
12	Antiviral Agents (Antivirals)IBA 01/2022 - 10/2003
12	Neutralizing AntibodiesIBA 01/2022 - 09/2006
12	AutoantigensIBA 11/2021 - 01/2004
10	COVID-19 VaccinesIBA 08/2022 - 01/2021
8	InterferonsIBA 03/2022 - 01/2012
8	Immunoglobulin G (IgG)IBA 01/2022 - 12/2009
8	Immunoglobulin E (IgE)IBA 10/2021 - 07/2012
7	SynucleinsIBA 01/2022 - 01/2017
7	Glycoproteins (Glycoprotein)IBA 02/2021 - 09/2003
7	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 02/2008
7	Histocompatibility Antigens Class IIBA 01/2019 - 11/2002
6	NucleoproteinsIBA 01/2022 - 10/2003
6	Viral AntigensIBA 11/2020 - 12/2015
6	HLA-A*02:01 antigenIBA 06/2012 - 04/2005
5	Messenger RNA (mRNA)IBA 08/2022 - 03/2021
5	Viral RNAIBA 03/2022 - 06/2009
5	LigandsIBA 02/2022 - 09/2013
5	BNT162 VaccineIBA 01/2022 - 01/2021
5	Interleukin-2 (IL2)IBA 01/2022 - 11/2010
5	EnzymesIBA 01/2021 - 05/2002
5	HLA-B Antigens (HLA-B)IBA 01/2014 - 04/2006
4	Apolipoproteins B (ApoB)IBA 07/2022 - 04/2017
4	HLA-DR Antigens (HLA-DR)IBA 03/2022 - 01/2004
4	Amino Acids FDA Link 01/2022 - 03/2004
4	Interferon-gamma (Interferon, gamma)IBA 11/2021 - 05/2004
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2009
4	RNA (Ribonucleic Acid)IBA 01/2021 - 12/2008
4	HLA-A Antigens (HLA-A)IBA 01/2019 - 05/2010
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 02/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 01/2015
3	ChemokinesIBA 03/2022 - 06/2020
3	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 03/2022 - 01/2017
3	Viral ProteinsIBA 01/2022 - 04/2015
3	Subunit VaccinesIBA 01/2021 - 01/2012
3	Recombinant ProteinsIBA 01/2020 - 07/2006
3	Interleukin-10 (Interleukin 10)IBA 01/2020 - 07/2005
3	Attenuated VaccinesIBA 01/2020 - 01/2017
3	oxidized low density lipoproteinIBA 04/2017 - 01/2013
3	GliadinIBA 01/2017 - 03/2003
3	HLA-DRB1 Chains (HLA DRB1)IBA 10/2016 - 01/2010
3	Indicators and Reagents (Reagents)IBA 01/2014 - 05/2010
3	CaspasesIBA 07/2013 - 12/2007
3	Glutens (Glutelin)IBA 01/2013 - 02/2008
2	Rituximab (Mabthera)FDA Link 08/2022 - 11/2021
2	ocrelizumabIBA 08/2022 - 01/2022
2	sinovac COVID-19 vaccineIBA 07/2022 - 01/2021

Therapy/Procedure

25	Therapeutics 08/2022 - 05/2002
21	Immunotherapy 10/2021 - 01/2002
7	Transplantation 01/2021 - 09/2009